This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients with androgenetic alopecia (AGA).

Inclusion Criteria:

• Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year

Exclusion Criteria:

• History of Paget's disease, osteoporosis, or bone malignancy
• History of bone fracture within the previous 12 months, except for metatarsal, metacarpal, or skull fractures
• Patient is currently undergoing radiation therapy or anticipates undergoing radiation therapy at any time during the study
• Drug or alcohol abuse within 12 months
• HIV positive
• Received hair transplants or had scalp reductions
• Use of hair weaves, hair extensions or wigs within 3 months
• Application of topical medications, minoxidil or nonsteroidal anti-inflammatory drugs (NSAIDs) to scalp within 4 weeks